Celldex Therapeutics (CLDX) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Celldex Therapeutics (CLDX) over the last 10 years, with Q3 2025 value amounting to -$1.01.
- Celldex Therapeutics' EPS (Weighted Average and Diluted) fell 5781.25% to -$1.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.38, marking a year-over-year decrease of 3100.78%. This contributed to the annual value of -$2452.1 for FY2024, which is 8387444.28% down from last year.
- As of Q3 2025, Celldex Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.01, which was down 5781.25% from -$0.85 recorded in Q2 2025.
- Celldex Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.34 during Q2 2021, with a 5-year trough of -$731.42 in Q4 2024.
- In the last 5 years, Celldex Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.62 in 2023 and averaged -$39.09.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first soared by 9994.18% in 2021, then tumbled by 8697419.61% in 2024.
- Over the past 5 years, Celldex Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.43 in 2021, then tumbled by 32.56% to -$0.57 in 2022, then tumbled by 47.37% to -$0.84 in 2023, then crashed by 86974.2% to -$731.42 in 2024, then soared by 99.86% to -$1.01 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$1.01 for Q3 2025, versus -$0.85 for Q2 2025 and -$0.81 for Q1 2025.